Visiongain has published a new report on Tumour Ablation Market Report 2021-2031: Forecasts by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Tumor Ablation market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. Technological innovations in the area of tumor ablation combined with increased procedural safety profile, rising market demand of minimal intrusive tumor ablation techniques, increasing pervasiveness of cancer across the globe, as well as growing number of public-private initiatives & funding to support ongoing research activities related to tumor ablation are boosting the growth of the market. However, factors such as critical regulatory policies and cost restraint measures implemented by various governments are limiting the optimal market growth.

COVID-19 Impact on Tumor Ablation Market
The pandemic of COViD-19 will not affect the growth of the Tumor Ablation market in any ways. The market growth is directly related to the occurrence of cancer among the masses, which is growing with a considerable growth rate.

Market Drivers
The rising occurrence of cancer and the high demand for harmless healing options are major factors directing towards the growth of the market. As per the report of the WHO, it is projected that around 10 to 11 million cancer cases will be diagnosed each year worldwide, till 2030. The number of new cancer cases is projected to increase by more than 80% in low-income countries compared to half the rate in high-income countries (40%) from 2008 to 2030. Lucrative growth potential in currently available therapeutic options, and high demand for minimally and non-intrusivetreatments are the factors expected to drive the market during the forecast period.

Market Opportunities
Growth potential offered by emerging market, owing to the rise in the healthcare spending globally is boosting the tumor ablation market growth. Additionally, growing awareness about Ablation procedures over conventional therapeutic and surgical procedures is also one of the significant factor paving towards the market growth.

Competitive Landscape
Some of the companies profiled in the report include AngioDynamics, Inc. (U.S.), Boston Scientific Corporation (U.S.), Galil Medical, Inc. (U.S.), EDAP TMS S.A. (France), Healthtronics, Inc. (U.S.), Medtronic, PLC (U.S.), Mermaid Medical, Inc. (Denmark), Mesonix, Inc. (U.S.), Neuwave Medical, Inc. (U.S.) and Sonacare Medical, LLC (U.S.).

Recent Developments
• In October 2015, AngioDynamics, Inc. introduced its NanoKnife Ablation system in South Korea after gettingsupervisory approval by Ministry of Food and Drug Safety (South Korea). This helped AngioDynamics enlarge its product portfolio for tumor ablation market.
• In July 2016, Boston Scientific Corporation bought the Cosman Medical Inc. (U.S.) at an undisclosed value. Cosman Medical is a leading manufacturer of radiofrequency ablation devices. This acquisition helped Boston Scientific to strengthen its technological capabilities and to increase its product sales and distribution network in the global tumor ablation market.
• In May, 2016, Galil Medical Inc. was acquired by the BTG PLC group (a part of BTG International Ltd, U.K.); for a value of USD 110.0 million. BTG International is prominent manufacturer of Cryoablation products and possesses strong product distribution network across Europe. The acquisition helped Galil Medical to strengthen its technological capabilities and to expand its distribution network in global tumor ablation market
• In April 2016, Medtronic plc launched Barrx 360 Express radiofrequency ablation (RFA) balloon catheter; for the treatment of Barrett's oesophagus. It helped the company to provide technologically advanced product to its customers in tumor ablation market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.